导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.87% | 1574/1840 |
| 近一周 | -5.24% | 1976/2029 |
| 近一月 | -1.88% | 488/2018 |
| 近一季 | -0.91% | 466/1966 |
| 近半年 | -15.08% | 1508/1877 |
| 近一年 | -19.40% | 1554/1753 |
| 近两年 | 5.39% | 1269/1324 |
| 近三年 | -20.55% | 971/1010 |
| 成立以来 | 54.13% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.30% 4085/4961 |
-15.90% 4707/5312 |
- - |
- - |
| 2025 | 3.27% 3138/4813 |
-3.28% 3032/3635 |
2.92% 1269/4076 |
4.07% 3702/4524 |
-0.31% 2459/4813 |
| 2024 | -0.97% 2145/3463 |
-4.90% 1794/2808 |
-5.99% 1827/3014 |
14.19% 2029/3129 |
-3.00% 2229/3463 |
| 2023 | -14.21% 1589/2656 |
3.91% 1092/2280 |
-10.17% 2093/2385 |
-2.12% 621/2515 |
-6.10% 1627/2655 |
| 2022 | -5.88% 123/2207 |
-8.93% 304/1919 |
5.12% 938/2016 |
-8.46% 199/2113 |
7.40% 314/2208 |
| 2021 | 22.26% 153/1822 |
-6.35% 997/1255 |
15.45% 224/1330 |
-0.10% 477/1466 |
13.18% 77/1822 |
| 2020 | - - |
- - |
- - |
20.13% 61/1164 |
10.96% 574/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 宏利消费红利指数C VS. 长安沪深300非周期A(740101) |